

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

ANNOUNCEMENT
PROPOSED CHANGE OF NON-EXECUTIVE DIRECTOR
AND VICE CHAIRMAN

The board (the “**Board**”) of directors (the “**Director(s)**”) of Biosino Bio-Technology and Science Incorporation (the “**Company**”) hereby announces that the second meeting of the eighth session of the Board was convened on 19 July 2023 by way of circulation of written resolutions by all members of the Board, at which, the following resolution was considered and passed:

In accordance with the relevant requirements of the Company Law of the People's Republic of China and the Articles of Association of the Company, Mr. Yang Peng (楊鵬) (“**Mr. Yang**”) was recommended by Institute of Biophysics of the Chinese Academy of Sciences (中國科學院生物物理研究所), a substantial shareholder of the Company, and has been nominated by the nomination committee of the Company as a candidate for a non-executive Director and a vice chairman of the Company, to replace Dr. Sun Zhe (孫哲) (“**Dr. Sun**”), an existing non-executive Director and vice chairman of the Company. This nomination will be proposed at the next general meeting of the Company for consideration. If appointed, Mr. Yang's term of office will be from the date of approval at the general meeting until the expiration of the current session of the Board.

Dr. Sun will cease to perform his duties as a non-executive Director and a vice chairman of the Company upon the conclusion of such general meeting should the resolution in relation to the proposed appointment of Mr. Yang be passed by the shareholders of the Company.

Dr. Sun has confirmed that he has no disagreement with the Board and there is no other matter that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The biographical details of Mr. Yang are set out below:

Mr. Yang, aged 49, obtained a master degree of management science and engineering from the Graduate School of Chinese Academy of Sciences* (中國科學院研究生院) (currently named as University of Chinese Academy of Sciences) in 2006. Mr. Yang has worked for the Chinese Academic of Sciences for over 20 years. Mr. Yang started working in the Chinese Academy of Sciences since July 2001 and is currently a director of the Assets and Finance Division* (資產財務處) and the Science and Communication Division* (科學傳播處) in the Institute of Biophysics of the Chinese Academic of Sciences.

As at the date of this announcement, save as disclosed above, Mr. Yang (i) has not held any other position in the Company or other subsidiaries; (ii) has not held any directorship in other listed companies in the last three years and has no other major appointments or professional qualifications; and (iii) does not have any relationships with any Directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company. Mr. Yang does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company has yet to fix the remuneration of Mr. Yang. The Board will consider the duties of Mr. Yang in the Company with reference to the remunerations of other Directors in determining the remuneration of Mr. Yang.

The Board is not aware that there are any other matters relating to the proposed appointment of Mr. Yang that need to be brought to the attention of the shareholders of the Company and there is no other information relating to Mr. Yang which is required to be disclosed pursuant to any of the requirements of Rule 17.50(2) of the Rules Governing the Listing of Securities on GEM of the Stock Exchange.

A circular containing, among other things, details of the proposed appointment of Mr. Yang as a non-executive Director, together with a notice convening the general meeting, will be despatched to the shareholders of the Company in due course.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman and Executive Director

Beijing, the PRC, 24 July 2023

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and non-executive Directors

Dr. Sun Zhe (孫哲博士) and Mr. Chen Zhengyong (陳正永先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangang (沈劍剛教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.